ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Safety and economic benefits of early hospital-at-home transfer after kidney transplantation: a propensity-score matched study from Spain.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplant units worldwide face the challenge of decreasing length of hospital stay (LOHS) after transplantation, while maintaining optimal outcomes and excellence in care. The Hospital-at-Home (HaH) model has already been applied with this goal after complex surgical procedures, but evidence in solid-organ transplantation is lacking. At our Institution, we implemented a protocol for early transfer at HaH for kidney transplant recipients (KTR) starting from post-operative day 4. We report herein the outcomes of the first 100 KTRs managed with this protocol, compared with a historical cohort from a time-period (2013-2019) when the HaH protocol was not operative yet. Controls were 1:1 matched with a propensity score (PSM) using a caliper of 0.05 on 13 key donor and recipients' characteristics, type of immunosuppression and delayed graft function. Results show no differences for 1-year rejection, renal function, patient and graft survival. Importantly, patients transferred to HaH had significantly shorter median LOHS (5[4-6] versus 9[8-15] days, P < 0.001). The median duration of HaH admission was 5[3-11] days. The combined duration of hospital plus HaH admission in the modern cohort (10[8-18] days) was not different from historical cohort LOHS (P = 0.117). Readmission rates at 30 and 90 days were similar between groups. This optimized management translated into lower costs of the HaH cohort (31874 ± 9114 versus 35780 ± 15720€, P = 0.033) for the whole transplantation process, mainly driven by reduced ward stay and in-hospital medication. We conclude that, in our experience, early transfer to HaH after transplantation optimized health-associated resources, while maintaining adequate clinical outcomes.
Indexed as
Identifiers
42518093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.